Connect with us
[ad_1] RESEARCH SUMMARY Publication: Nature Genetics https://www.nature.com/articles/s41588-023-01307-z Dana-Farber Cancer Institute author: Cigall Kadoch, PhD, Summary: A new class of oral drugs can inhibit a wide...
[ad_1] Newswise — PLYMOUTH MEETING, PA [February 27, 2023] — Today, the National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading United States cancer centers—announced a...
[ad_1] Newswise — Early diagnosis of uterine cancer is known to improve a patient’s chances for survival, but previous research has found that Black patients are...
[ad_1] Newswise — UC Davis Comprehensive Cancer Center is partnering with TargaGenix and Northeastern University to study pancreatic ductal adenocarcinoma (PDAC). The often-lethal cancer has an...
[ad_1] Newswise — Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according...
[ad_1] RESEARCH SUMMARY Study Title: An atlas of substrate specificities for the human serine/threonine kinome Publication: Nature (Online) January 11, 2023 https://www.nature.com/articles/s41586-022-05575-3 Dana-Farber Cancer Institute author:...
[ad_1] Newswise — This month Louisiana State University-Louisiana Children’s Medical Center (LSU-LCMC) Health Cancer Center became the 108th member of the Association of American Cancer Institutes...
[ad_1] Newswise — HOUSTON ― Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T...
[ad_1] Newswise — The Association of American Cancer Institutes (AACI) is pleased to add Ellis Fischel Cancer Center, a part of University of Missouri (MU) Health...
[ad_1] Newswise — Research conducted by UC Davis Comprehensive Cancer Center and the University of Cincinnati shows that direct oral anti-coagulant (DOAC) drugs are more effective...
[ad_1] Newswise — In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety profile in heavily...
[ad_1] ********** UNDER EMBARGO UNTIL Saturday, December 10 at 5:10 PM EST (4:10 PM CST) *********** Newswise — New Brunswick, NJ and Boston, MA, December 10,...
[ad_1] Newswise — SEATTLE — Dec. 1, 2022 — The 64th Annual Meeting and Exposition of the American Society of Hematology (ASH) will take place virtually...
[ad_1] Newswise — HOUSTON – Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment over three weeks instead...
[ad_1] Newswise — PLYMOUTH MEETING, PA, UNITED STATES [November 2, 2022] — The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United...
[ad_1] Newswise — Memorial Sloan Kettering Cancer Center (MSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (Cotellic®) for the...
[ad_1] Newswise — New Brunswick, N.J., November 1, 2022 – It’s not unusual for cysts to form in the pancreas, an important organ that produces enzymes that...
[ad_1] Newswise — HOUSTON ― In recognition of her trailblazing work uncovering the mechanisms of the p53 tumor suppressor, Guillermina “Gigi” Lozano, Ph.D., chair of Genetics...
[ad_1] Newswise — HOUSTON ― The University of Texas MD Anderson Cancer Center will host its virtual Leading Edge of Cancer Research Symposium from November 17-18,...
[ad_1] Newswise — NEW YORK, September 27, 2022 – The Cancer Research Institute (CRI), a nonprofit organization dedicated to harnessing the immune system’s power to control...